SCHEMBL5120085

SCHEMBL5120085

COc1cccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC20A2 Q08357 1/20 0.63
SLC20A1 Q8WUM9 1/20 0.63
SLC10A6 Q3KNW5 2/20 0.58
SLC10A2 Q12908 1/20 0.58
SLC10A1 Q14973 1/20 0.58
GPR27 Q9NS67 3/20 0.56
AVPR2 P30518 2/20 0.56
CCR9 P51686 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
MAPT P10636 2/20 0.53
TP53 P04637 1/20 0.53
KCNA5 P22460 1/20 0.53
EGFR P00533 1/20 0.53
FGFR1 P11362 1/20 0.53
KDR P35968 1/20 0.53
IDH1 O75874 1/20 0.53
MEN1 O00255 1/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111523 0.90 SLC10A6 (0.61) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL5126815 0.88 KCNA5 (0.58) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL10249599 0.88 GPR27 (0.66) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL5110940 0.88 SLC10A6 (0.68) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL5126770 0.88 SLC10A6 (0.67) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL5124913 0.86 SLC10A6 (0.57) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL5115547 0.86 SMN1; SMN2 (0.64) SLC10A6SLC10A2SLC10A1GPR27AVPR2
SCHEMBL7126685 0.85 SLC20A2 (0.83) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL491680 0.85 SLC10A6 (0.60) SLC20A2SLC20A1SLC10A6SLC10A2SLC10A1
SCHEMBL492243 0.83 SLC10A6 (0.58) SLC10A6SLC10A2SLC10A1GPR27AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 SLC20A2 2520/4885SLC20A1 1828/4885SLC10A6 2987/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 SLC20A2 2537/4885SLC20A1 1974/4885SLC10A6 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.